Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), ...

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...

Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, 2021. REUTERS/Brendan McDermid/File Photo Abbott Laboratories on ...

LabVantage Pharma is the only pre-configured and pre-validated pharmaceutical LIMS in the world. This greatly lowers the deployment cost (85%) and time (75%) compared to a traditional LIMS ...

Perform material- and labor-effective extrusion with Thermo Scientific™ Pharma 11 Twin-screw Extruder, which requires only a small amount of active pharmaceutical ingredient, operating at ...

Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of ...

In a statement, Cytokinetics said that part of the Royalty Pharma cash will go towards the commercial launch of cardiac myosin inhibitor aficamten, which is being prepared for filing in the US and ...

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.

Sanofi S.A. Part Cert 0.06% €8.19M ...

IPC Indice de Precios Y Cotizaciones 49,940.89-7.26-0.01% ...